GILEAD SCIENCES, INC. Payments to Acquire Available-for-sale Securities, Equity
GILEAD SCIENCES, INC. (GILD) reported Payments to Acquire Available-for-sale Securities, Equity of $140.00 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity · last filed 2018-11-06
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities, equity for the quarter ending 2018-09-30 was $38.00M.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities, equity for the quarter ending 2018-06-30 was $82.00M.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities, equity for the quarter ending 2018-03-31 was $20.00M.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities, equity for the quarter ending 2017-09-30 was $0.00.
| Period end | Payments to Acquire Available-for-sale Securities, Equity 3 month | Payments to Acquire Available-for-sale Securities, Equity 6 month | Payments to Acquire Available-for-sale Securities, Equity 9 month |
|---|---|---|---|
| 2018-09-30 | $38.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $120.00M derived: sum of 2 quarters · filed 2018-11-06 | $140.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $82.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $102.00M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $20.00M 10-Q · filed 2018-05-09 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $0.00 10-Q · filed 2018-08-06 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-09 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $357.00M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $357.00M 10-Q · filed 2017-08-07 | |
| 2016-03-31 | $357.00M 10-Q · filed 2017-05-10 | ||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $0.00 derived: sum of 2 quarters · filed 2016-11-07 | $0.00 10-Q · filed 2016-11-07 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $0.00 10-Q · filed 2016-08-05 | |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |